Fig. 7

The FOXM1–Survivin axis was up-regulated in gliomas and related to poor prognosis. a RT-qPCR measuring mRNA levels of FOXM1 and Survivin in para-tumor brain tissues (n = 10), WHO grade I–II gliomas (n = 10), WHO grade III gliomas (n = 10), and WHO grade IV gliomas (GBMs, n = 10). The correlation between FOXM1 and Survivin mRNA levels was analyzed via GraphPad Prism 7.0 using Pearson R test. b TCGA data of FOXM1/Survivin mRNA expression (mRNA Expression z-Scores, RNA SeqV2 RSEM) in LGGs (n = 530), GBMs (n = 166), and normal brain tissues (n = 10). The correlation between FOXM1 and Survivin mRNA levels (696 samples in total) was analyzed using GraphPad Prism 7.0 and Pearson R test. c Kaplan–Meier survival analysis of the prognostic role of FOXM1/Survivin using TCGA data (692 samples in total). The samples were divided into a high and low FOXM1/Survivin expression group using their relative median mRNA level. d Left part, representative images of IHC staining of FOXM1 and Survivin in para-tumor brain tissues and gliomas (scale bar, 100 μm). Right part, IHC intensity was measured and processed by Image-pro Plus 6.0. The correlation between FOXM1 and Survivin IHC intensity was analyzed using GraphPad Prism 7.0 and Pearson R test. e Kaplan–Meier survival analysis of the prognostic role of FOXM1 and Survivin. The samples were divided into high and low FOXM1/Survivin expression groups by the median IHC intensity. *P < 0.05; **P < 0.01. RT-qPCR reverse transcription-quantitative polymerase chain reaction, PT para-tumor brain tissue, WHO World Health Organization, LGG low-grade glioma, GBM glioblastoma multiforme, TCGA The Cancer Genome Atlas, RSEM RNA-seq by expectation maximization, IHC immunohistochemistry